Zevin Asset Management LLC Acquires 19,416 Shares of Novo Nordisk A/S (NYSE:NVO)

Zevin Asset Management LLC grew its holdings in Novo Nordisk A/S (NYSE:NVO) by 47.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 60,708 shares of the company’s stock after purchasing an additional 19,416 shares during the period. Zevin Asset Management LLC’s holdings in Novo Nordisk A/S were worth $5,222,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of NVO. Aigen Investment Management LP bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth $297,000. Aptus Capital Advisors LLC increased its holdings in shares of Novo Nordisk A/S by 33.2% in the 3rd quarter. Aptus Capital Advisors LLC now owns 3,774 shares of the company’s stock worth $449,000 after purchasing an additional 940 shares in the last quarter. MQS Management LLC bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth $363,000. Main Street Financial Solutions LLC increased its holdings in shares of Novo Nordisk A/S by 11.5% in the 3rd quarter. Main Street Financial Solutions LLC now owns 3,681 shares of the company’s stock worth $438,000 after purchasing an additional 381 shares in the last quarter. Finally, Huntington National Bank increased its holdings in shares of Novo Nordisk A/S by 12.8% in the 3rd quarter. Huntington National Bank now owns 18,209 shares of the company’s stock worth $2,168,000 after purchasing an additional 2,065 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on NVO. Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday. Morgan Stanley began coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Thursday. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $77.22 on Friday. The business’s fifty day moving average is $83.95 and its 200 day moving average is $103.24. Novo Nordisk A/S has a fifty-two week low of $73.80 and a fifty-two week high of $148.15. The company has a market capitalization of $346.54 billion, a PE ratio of 23.47, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Sell-side analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a $0.7874 dividend. This represents a dividend yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s payout ratio is presently 47.72%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.